Systemic anticancer therapy near the end of life and acute health care utilization: A target trial emulation study using SEER–Medicare.
612 Background: Use of Systemic anticancer therapy (SACT) at end-of-life (EOL) has been associated with higher costs, increased hospitalizations (HL), emergency department (ED), and intensive care unit (ICU) utilization and lower hospice (HP) use all of which may adversely affect quality of life. Prior studies...